Previous Pause Next Astellas Names Michael Petroutsas as Head of US Commercial Read More Learn more about how our culture supports working parents to succeed Read More Meet Our Working Parents of the Year Read More Astellas Celebrates Global Diversity Awareness Month Read More Astellas Scores 100 Again on Disability Equality Index for Fourth Consecutive Year Read More Astellas Pledges to End Cancer Stigma in the Workplace Read More Learn more about how Astellas is prioritizing treatments to support women's health Read More Learn more about our clinical trials and educational resources on the clinical trial process. Read More 1 2 3 4 5 6 7 8 News Press Releases News / Press ReleasesApr 23, 2024Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment SettingRead More News / Press ReleasesApr 21, 2024Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery ProgramsRead More News / Press ReleasesMar 28, 2024China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder CancerRead More
Patient FocusLearn more about our commitment to patients and available resourcesRead MoreInvestorsAccess financial information, investor relations library, analyst coverage and moreRead MoreContact UsCall us at (800) 888-7704, M-F, 8AM-7PM CTRead More